Literature DB >> 10774881

Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations.

M M Welling1, A Paulusma-Annema, H S Balter, E K Pauwels, P H Nibbering.   

Abstract

The aim of this study was to select technetium-99m labelled peptides that can discriminate between bacterial infections and sterile inflammations. For this purpose, we first assessed the binding of various 99mTc-labelled natural or synthetic peptides, which are based on the sequence of the human antimicrobial peptide ubiquicidin (UBI) or human lactoferrin (hLF), to bacteria and to leucocytes in vitro. In order to select peptides that preferentially bind to bacteria over host cells, radiolabelled peptides were injected into mice intraperitoneally infected with Klebsiella pneumoniae (K. pneumoniae) and the amount of radioactivity associated with the bacteria and with the leucocytes was quantitated. The next phase focussed on discrimination between bacterial infections and sterile inflammatory processes using 99mTc-labelled peptides in mice intramuscularly infected with various bacteria (e.g. multi-drug-resistant Staphylococcus aureus) and in animals that had been injected with lipopolysaccharides (LPS) of bacterial origin to create a sterile inflammatory process. Also, we studied the distribution of 99mTc-labelled UBI 29-41 and UBI 18-35 in rabbits having an experimental thigh muscle infection with K. pneumoniae and in rabbits injected with LPS. Based on the results of our in vitro and in vivo binding assays, two peptides, i.e. UBI 29-41 and UBI 18-35, were selected as possible candidates for infection imaging. The radiolabelled peptides can detect infections with both gram-positive and gram-negative bacteria in mice as early as 5-30 min after injection, with a target-to-non-target (T/NT) ratio between 2 and 3; maximum T/NT ratios were seen within 1 h after injection. In rabbits, high T/NT ratios (>5) for 99mTc-labelled UBI 29-41 were observed from 1 h after injection. No accumulation of the selected 99mTc-labelled UBI-derived peptides was observed in thighs of mice and rabbits previously injected with LPS. Scintigraphic investigation into the biodistribution of 99mTc-labelled UBI peptides revealed that these peptides were rapidly removed from the circulation by renal excretion. Similar data were observed for 99mTc-labelled defensin 1-3. Our data for 99mTc-labelled hLF and related peptides indicate that these compounds are less favourable for infection detection. Taken together, 99mTc-labelled UBI 18-35 and UBI 29-41 enable discrimination between bacterial infections and sterile inflammatory processes in both mice and rabbits. Based on their characteristics, we consider these peptides the candidates of preference for detection of bacterial infections in man.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10774881     DOI: 10.1007/s002590050036

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  50 in total

1.  Concerns about 99mTc-labelled ciprofloxacin for infection detection.

Authors:  K E Britton; D W Wareham; S S Das
Journal:  Eur J Nucl Med       Date:  2001-06

Review 2.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo.

Authors:  Mick M Welling; Carlo P J M Brouwer; Wim van 't Hof; Enno C I Veerman; Arie V Nieuw Amerongen
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  Evaluation of Peptide-Based Probes toward In Vivo Diagnostic Imaging of Bacterial Biofilm-Associated Infections.

Authors:  Landon W Locke; Kothandaraman Shankaran; Li Gong; Paul Stoodley; Samuel L Vozar; Sara L Cole; Michael F Tweedle; Daniel J Wozniak
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

5.  Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  J M Sierra; D Rodriguez-Puig; A Soriano; J Mensa; C Piera; J Vila
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

6.  The unusual structure of Ruminococcin C1 antimicrobial peptide confers clinical properties.

Authors:  Clarisse Roblin; Steve Chiumento; Olivier Bornet; Matthieu Nouailler; Christina S Müller; Katy Jeannot; Christian Basset; Sylvie Kieffer-Jaquinod; Yohann Couté; Stéphane Torelli; Laurent Le Pape; Volker Schünemann; Hamza Olleik; Bruno De La Villeon; Philippe Sockeel; Eric Di Pasquale; Cendrine Nicoletti; Nicolas Vidal; Leonora Poljak; Olga Iranzo; Thierry Giardina; Michel Fons; Estelle Devillard; Patrice Polard; Marc Maresca; Josette Perrier; Mohamed Atta; Françoise Guerlesquin; Mickael Lafond; Victor Duarte
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

7.  Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models.

Authors:  Naeem-Ul-Haq Khan; Syed Ali Raza Naqvi; Hamza Sohail; Samina Roohi; Muhammad Asghar Jamal
Journal:  Mol Biol Rep       Date:  2019-03-30       Impact factor: 2.316

8.  Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.

Authors:  Jyotsna Bhatt; Archana Mukherjee; Aruna Korde; Mukesh Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

Review 9.  Radionuclide imaging of spinal infections.

Authors:  Filip Gemmel; Nicolas Dumarey; Christopher J Palestro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10       Impact factor: 9.236

10.  Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis.

Authors:  Elena Lazzeri; Ernest K J Pauwels; Paola A Erba; Duccio Volterrani; Mario Manca; Lisa Bodei; Donatella Trippi; Antonio Bottoni; Renza Cristofani; Vincenzo Consoli; Christopher J Palestro; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.